Filing Flows › Pacira BioSciences (PCRX) › Q2 2026
Pacira BioSciences (PCRX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 4, 2026
Pacira BioSciences (PCRX) reported revenue of $192M for the second quarter 2026 (Q2 2026), +6% from a year earlier and +8% from the quarter before. Operating margin was 2.2%, net earnings $4.7M (2.4% of revenue).
Pacira BioSciences, Q2 2026: revenue $192M (+6% year over year), operating margin 2.2%, net earnings $4.7M, operating cash flow $57.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $192M | +8% | +6% |
| Operating profit | $4.3M | -38% | -50% |
| Net earnings | $4.7M | +60% | — |
| Operating cash flow | $57.5M | +124% | +378% |
| Free cash flow | $56.1M | +144% | +503% |
What changed
Revenue was $192.4M in Q2 2026, up 6% year over year and up 8% from the previous quarter. EXPAREL was the largest line at 77% of revenue. EXPAREL added $4.9M year over year (up 3%), 43% of the total change.
Operating profit was $4.3M, a 2.2% margin (down 2.5 points year over year). Operating profit fell $4.2M even though revenue rose $11.3M versus Q2 2025, so costs grew faster than sales. Total costs grew 9% against revenue growth of 6%. The fastest-growing cost line was Other operating costs (+47%). Net earnings were $4.7M. The effective tax rate was -82.1%.
Operating cash flow was $57.5M (up 378% year over year), 1235% of net earnings. Non-cash charges added back $21.3M of depreciation and amortization and $15.0M of share-based compensation. Working capital and other items added $16.6M. Capital expenditures of $1.3M left free cash flow of $56.1M.
Questions
What was Pacira BioSciences' revenue in the second quarter 2026?
Pacira BioSciences (PCRX) reported revenue of $192M for the second quarter 2026 (Q2 2026), +6% from a year earlier and +8% from the quarter before.
Was Pacira BioSciences profitable in the second quarter 2026?
Operating profit was $4.3M (2.2% of revenue) and net earnings $4.7M.
Source: Pacira BioSciences 10-Q on SEC EDGAR.